Related Research Articles
Combined injectable contraceptives (CICs) are a form of hormonal birth control for women. They consist of monthly injections of combined formulations containing an estrogen and a progestin to prevent pregnancy.
Estradiol benzoate (EB), sold under the brand name Progynon-B among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for transgender women, and in the treatment of gynecological disorders. It is also used in the treatment of prostate cancer in men. Estradiol benzoate is used in veterinary medicine as well. When used clinically, the medication is given by injection into muscle usually two to three times per week.
Estradiol cypionate (EC), sold under the brand name Depo-Estradiol among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for trans women, and in hormonal birth control for women. It is given by injection into muscle once every 1 to 4 weeks.
Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth.
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations. OHPH is given by injection into muscle at regular intervals.
ñ
The pharmacology of estradiol, an estrogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.
Estradiol benzoate/progesterone (EB/P4), sold under the brand names Duogynon and Sistocyclin among others, is a combination medication of estradiol benzoate (EB), an estrogen, and progesterone (P4), a progestogen. It has been formulated both as short-acting oil solutions and long-acting microcrystalline aqueous suspensions and is given by injection into muscle either once or continuously at regular intervals.
Estrone/progesterone (E1/P4), sold under the brand name Synergon, is a combination medication formulation of estrone, an estrogen, and progesterone, a progestogen. E1/P4 is used as an injectable preparation to induce withdrawal bleeding in women with non-pregnancy-related amenorrhea . It has also sometimes been used off-label as an abortifacient. The medication comes in a three-ampoule pack, contains 1 mg estrone and 10 mg progesterone per ampoule, and is administered by intramuscular injection. The usual dose of the medication is three injections, each two days apart, with the treatment duration not exceeding one week. E1/P4 is or has been available in France, Monaco, and Turkey, as well as in some French-speaking African countries such as Benin and Cameroon. The medication has been marketed since at least 1952.
Estradiol hemisuccinate/progesterone (EHS/P4), sold under the brand name Hosterona, is an injectable combination medication of estradiol hemisuccinate (EHS), an estrogen, and progesterone (P4), a progestogen, which is used to induce withdrawal bleeding in women with non-pregnancy-related amenorrhea. It is provided in the form of ampoules containing 20 mg/2 mL EHS and 100 mg/2 mL P4 and is administered by intramuscular injection. The medication is available in Argentina and Paraguay.
Estradiol pivalate/progesterone (ETMA/P4), sold under the brand name Estrotate with Progesterone, is a combination medication of estradiol pivalate, an estrogen, and progesterone (P4), a progestogen, which was used in menopausal hormone therapy and the treatment of gynecological disorders but is no longer available. It contained 1 mg/mL ETMA and 10 mg/mL P4 in oil solution provided in vials and was administered by intramuscular injection at regular intervals.
Estradiol benzoate/testosterone propionate (EB/TP), sold under the brand name Bothermon, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone propionate (TP), an androgen/anabolic steroid. It contains 0.24 mg/mL EB and 4.76 mg/mL TP in oil solution in each ampoule and is administered by intramuscular injection. The medication was marketed in Japan by 1953 and remains available in this country today.
Estradiol benzoate/estradiol valerate/norethisterone acetate/testosterone enanthate (EB/EV/NETA/TE), sold under the brand name Ablacton, is an injectable combination medication of estradiol benzoate (EB), an estrogen, estradiol valerate (EV), an estrogen, norethisterone acetate (NETA), a progestin, and testosterone enanthate (TE), an androgen/anabolic steroid, which has been used to suppress lactation in women. It contains 5 mg EB, 8 mg EV, 20 mg NETA, and 180 mg TE in oil solution and is provided in the form of ampoules. It is given as a single intramuscular injection following childbirth. The medication was manufactured by Schering and was previously marketed in Italy and Spain, but is no longer available.
Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid. It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection. The medication was manufactured by Roussel and Théramex and was marketed by 1953. It is no longer available.
Estradiol benzoate/progesterone/methandriol dipropionate (EB/P4/MADP), sold under the brand name Progestandron (Organon), is an injectable combination medication of estradiol benzoate (EB), an estrogen, progesterone (P4), a progestogen, and methandriol dipropionate (MADP), an androgen/anabolic steroid. It contained 3 mg EB, 20 mg P4, and 50 mg MADP, was provided in the form of ampoules, and was administered by intramuscular injection. The medication was marketed by 1957. It is no longer available.
Estradiol benzoate/trenbolone acetate, sold under the brand names Synovex Choice, Synovex One, Synovex Plus, Synovex with Trenbolone Acetate, is an implantable combination medication of estradiol benzoate (EB), an estrogen, and trenbolone acetate, an androgen/anabolic steroid, which is used in veterinary medicine as a growth promoter for livestock. It is provided in the form of pellets of pure crystalline estradiol benzoate and trenbolone acetate and is administered by subcutaneous implantation at regular intervals.
Estradiol benzoate/progesterone/testosterone propionate (EB/P4/TP), sold under the brand names Lukestra, Steratrin, Trihormonal, and Trinestryl, is an injectable combination medication of estradiol benzoate (EB), an estrogen, progesterone (P4), a progestogen, and testosterone propionate (TP), an androgen/anabolic steroid. It contained 1 to 3 mg EB, 20 to 25 mg P4, and 25 mg TP, was provided in the form of ampoules, and was administered by intramuscular injection. The medication was introduced by 1949 and was marketed in the United States, the United Kingdom, and Germany among other places. It is no longer available.
References
- 1 2 3 Silló G (7–9 March 1957). "Komplexhormon bei Menopause und Hypertonie". Hormone und Psyche die Endokrinologie des Alternden Menschen. Fünftes Symposion der Deutschen Gesellschaft für Endokrinologie. Freiburg (Breisgau): Springer-Verlag. pp. 53–57 (55). ISBN 978-3-642-87014-9.
- ↑ Greenblatt RB, Barfield WE (January 1952). "Hormonal control of functional uterine bleeding". American Journal of Obstetrics and Gynecology. 63 (1): 153–7. doi:10.1016/S0002-9378(16)38992-X. PMID 14894511. S2CID 6863371.
The estrogen-progesterone-testosterone combinations used in our studies were supplied by the following pharmaceutical companies: Wyeth, Inc.: Tristerone (6 mg. estrone, 50 mg. progesterone, 25 mg. testosterone).Schering Corporation: Steratrin (1 mg. estradiol benzoate, 25 mg. progesterone, 25 mg. testoterone propionate).Sharp and Dohme, Inc.: Lukestra (1.66 mg. estradiol benzoate, 25 mg. progesterone, 25 mg. testosterone propionate).Ayerst, McKenna & Harrison Limited: Premarin Injectable, 20 mg. per vial of 5 c.c.
- ↑ General Practitioner. American Academy of General Practice. April 1962. p. 109.
Estrogen Therapy In an attempt to increase the theoretical effectiveness of testosterone and progesterone, some investigators have added estrogen to the parenteral mixture to form a triad of steroids in an aqueous suspension (Tristerone®).
- ↑ American Journal of Hospital Pharmacy. American Society of Hospital Pharmacists. 1958. p. 114.
Tristerone*, Injection (Progesterone, Testosterone, and Estrone) : 25 mg. of microcrystalline progesterone, 25 mg. of microcrystallinefree testosterone, and 6 mg. (60,000 I.U.) of microcrystalline estrone per 1-cc.
- ↑ American Professional Pharmacist. American Professional Pharmacist, Incorporated. 1951. p. 515.
TRISTERONE (Crystalline Progesterone, Testosterone, and Estrone Wyeth)
- ↑ "?". IBM Watson Health.
- ↑ "Tristeron". Drugs.com.[ permanent dead link ]
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |